New pill takes on aggressive brain tumors in early trial

NCT ID NCT07464925

Recruiting now Disease control Sponsor: Tetragon Biosciences Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-stage trial tests an oral drug called GLIX1 in 30 adults with recurrent or progressive high-grade glioma, a fast-growing brain cancer. The study aims to find the safest dose and check for any signs of tumor control. Participants take the drug daily until their disease gets worse or side effects become unacceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLIX1 (oral capsule)
What this could lead to: If it works, this could point toward a new treatment option for people with aggressive brain tumors that have come back after standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 30 people. The main goal is safety and dosing, not yet proof of effectiveness. Side effects are unknown and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain glioblastoma glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME OF BRAIN GLIOMA

Contacts and locations

Show contact details

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States

Contact Email: •••••@•••••
Northwestern Medicine
RECRUITING

Chicago, Illinois, 60611, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.